Please ensure Javascript is enabled for purposes of website accessibility

Stock Markets Climb Wednesday Morning; Why Traders Hate the Livongo-Teladoc Deal

By Dan Caplinger - Aug 5, 2020 at 12:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Solid earnings results from major companies were a big positive for the broader market.

Investors have anticipated a painful earnings season because of the COVID-19 pandemic. To see things turn out better than expected, therefore, has given the stock market a shot in the arm. Markets got a further lift on Wednesday morning, especially with Walt Disney (DIS 3.98%) giving investors a positive surprise. Just before 11 a.m. EDT, the Dow Jones Industrial Average (^DJI 1.63%) was up 284 points to 27,112. The S&P 500 (^GSPC 2.13%) rose 20 points to 3,326, and the Nasdaq Composite (^IXIC 0.00%) gained 29 points to 10,971.

One company whose earnings report seemed to go unnoticed was Livongo Health (LVGO). The diabetes glucose monitoring specialist announced another set of blockbuster results, but the news got overshadowed by an announcement that the high-growth healthcare stock had agreed to an acquisition by Teladoc Health (TDOC 6.72%). Both Livongo and Teladoc moved sharply lower in response as, at least in the short run, traders voiced their discontent with the strategic combination.

Screen with dozens of stock quotes and other data.

Image source: Getty Images.

Livongo's fundamentals are stronger than ever

For investors who just looked at Livongo's second-quarter financial report, things looked great. The company continued its string of impressive performances, pointing to the sound fundamental business prospects for the provider of remote monitoring services for diabetes patients.

Livongo's revenue jumped 125% from where it was 12 months ago, as a surge of new patients joined the service. Livongo now counts more than 410,000 members using its glucose monitoring, up 113% year over year. The company posted a minimal loss, and after adjusting for extraordinary items, Livongo said its adjusted earnings came in at $0.11 per share.

CEO Zane Burke's comments were positive. The leader pointed to the 75% rise in employers and health plan clients using Livongo, as virtual care becomes more commonplace, accepted, and necessary in the current healthcare environment. Moreover, Burke sees further opportunities for growth in expanding its already impressive leadership position.

What the deal means for Livongo and Teladoc

Yet the bigger news proved to be Teladoc's purchase of Livongo. Under the terms of the agreement, Livongo shareholders will receive 0.592 shares of Teladoc stock plus $11.33 in cash for every share of Livongo stock they own. Based on Teladoc's closing price on Tuesday, that worked out to around $159 per share in total compensation. That's roughly a 10% premium over where Livongo closed Tuesday afternoon.

Yet as often happens with acquisitions with a significant stock component, Teladoc shares dropped significantly. At its worst levels, Teladoc was down 20%, and closer to 11 a.m. EDT, the stock was still off 15%. That left the implied value of the deal closer to $135 per Livongo share. That's roughly where that stock traded Wednesday morning, down 7% after having been off twice that.

Some Livongo shareholders have to be disappointed at the fact that the deal will force them to accept slower overall growth rates from the combined company. Teladoc has grown at a healthy rate, and the prospects for its remote medical services getting a further boost are considerable. But the revenue growth can't match Livongo's pace. Some would inevitably prefer to keep Livongo separate and benefit solely from the expansion of its business.

For long-term investors, the question is whether Teladoc will help foster Livongo's success or simply subsume it into a slower-growing whole. Given just how sharply both stocks have risen in 2020, it's anyone's guess whether the healthcare businesses will be able to sustain their growth in a way that keeps both momentum traders and dedicated shareholders satisfied.

Dan Caplinger owns shares of Walt Disney. The Motley Fool owns shares of and recommends Livongo Health Inc, Teladoc Health, and Walt Disney and recommends the following options: long January 2021 $60 calls on Walt Disney and short October 2020 $125 calls on Walt Disney. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
TDOC
$37.79 (6.72%) $2.38
Livongo Health, Inc. Stock Quote
Livongo Health, Inc.
LVGO
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
^DJI
$33,309.51 (1.63%) $535.10
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
^GSPC
$4,210.24 (2.13%) $87.77
The Walt Disney Company Stock Quote
The Walt Disney Company
DIS
$112.43 (3.98%) $4.30
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
^IXIC
$12,493.93 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.